To systematically evaluate the efficacy and safety of Tanshinone ⅡA sulfonate combined with amiodarone in the treatment of acute myocardial infarction complicated with atrial fibrillation.Methods:PubMed,Cochrane library,Embase,CNKI,Wanfang,VIP were retrieved.All randomized controlled trial study literature which about the K tanshinone ⅡA sulfonate combined with amiodarone in the treatment of acute myocardial infarction complicated with atrial fibrillation were collected.Meta analysis was performed to evaluate the data by using RevMan5.3 software.Results:A total of 10 papers were included in the study,with a total of 1088 patients.The experimental group was 549 cases and the control group was 539 cases.Meta analysis results showed:The success rate of AF conversion of the experimental group was better than that of the control group［OR=3.10,95%CI(2.16~4.44),P<0.05］.The recurrence rate of atrial fibrillation［OR=0.32,95%CI(0.22~0.48),P<0.05］.The incidence of heart failure of the experimental group ［OR=0.23,95%CI(0.15~0.35),P<0.05］.The mortality ［OR=0.23,95%CI(0.15~0.35),P<0.05］.Heart failure incidence ［OR=0.23,95%CI(0.15~0.35),P<0.05］,mortality ［OR=0.23,95%CI(0.15~0.35),P<0.05］,the CRP level after treatment ［MD=-1.15，95%CI(-1.69~-0.61),P<0.05］.The adverse reactions rate ［OR=0.24，95%CI(0.12~0.49),P<0.05］.Conclusion:Tanshinone ⅡA sulfonate combined with amiodarone is safe and reliable in the treatment of acute myocardial infarction complicated with atrial fibrillation.However,more high-quality randomized controlled studies are needed to provide clinical evidence.